About the Authors

Marcelo A. Barria

Affiliations George and Cynthia Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, Texas, United States of America, Department of Neurology, University of Texas Houston Medical School, Houston, Texas, United States of America

Abhisek Mukherjee

Affiliations George and Cynthia Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, Texas, United States of America, Department of Neurology, University of Texas Houston Medical School, Houston, Texas, United States of America

Dennisse Gonzalez-Romero

Affiliations George and Cynthia Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, Texas, United States of America, Department of Neurology, University of Texas Houston Medical School, Houston, Texas, United States of America

Rodrigo Morales

Affiliations George and Cynthia Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, Texas, United States of America, Department of Neurology, University of Texas Houston Medical School, Houston, Texas, United States of America, Facultad de Ciencias, University of Chile, Santiago, Chile

Claudio Soto

claudio.soto@uth.tmc.edu

Affiliations George and Cynthia Mitchell Center for Neurodegenerative Diseases, University of Texas Medical Branch, Galveston, Texas, United States of America, Department of Neurology, University of Texas Houston Medical School, Houston, Texas, United States of America

Competing Interests

Dr. Soto is an inventor on the PMCA technology and a Founder, Vice-President and Chief Scientific Officer of Amprion Inc, a biotech company focusing on the development of early and sensitive diagnosis for prion diseases and other disorders involving protein misfolding.

Author Contributions

Conceived and designed the experiments: MAB CS. Performed the experiments: MAB AM DGR RM. Analyzed the data: MAB AM DGR CS. Wrote the paper: CS.